NCT00871936

Brief Summary

The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P25-P50 for phase_2 type-2-diabetes

Timeline
Completed

Started Apr 2009

Shorter than P25 for phase_2 type-2-diabetes

Geographic Reach
1 country

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 26, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 30, 2009

Completed
2 days until next milestone

Study Start

First participant enrolled

April 1, 2009

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2009

Completed
Last Updated

November 18, 2023

Status Verified

April 1, 2023

Enrollment Period

6 months

First QC Date

March 26, 2009

Last Update Submit

November 14, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Reduction in HbA1c

    12 weeks

Secondary Outcomes (1)

  • Adverse Events

    12 weeks

Study Arms (2)

1

EXPERIMENTAL

SLx-4090 in combination with Metformin

Drug: SLx-4090Drug: Metformin

2

OTHER

Placebo

Other: PlaceboDrug: Metformin

Interventions

SLx-4090

1
PlaceboOTHER

matching tablets

2
12

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HbA1c 7-11%
  • On a stable dose of metformin for at least 6 weeks

You may not qualify if:

  • Type 1 Diabetes
  • Antidiabetic medication other than or in addition to metformin
  • FPG \> 270 mg/dL

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Unknown Facility

Anaheim, California, 92801, United States

Location

Unknown Facility

Burbank, California, 91505, United States

Location

Unknown Facility

Los Angeles, California, 90036, United States

Location

Unknown Facility

Los Angeles, California, 90057, United States

Location

Unknown Facility

West Palm Beach, Florida, 33401, United States

Location

Unknown Facility

Addison, Illinois, 60101, United States

Location

Unknown Facility

Auburn, Maine, 04210, United States

Location

Unknown Facility

Charlotte, North Carolina, 28211, United States

Location

Unknown Facility

Hickory, North Carolina, 28602, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27103, United States

Location

Unknown Facility

Greenville, South Carolina, 29615, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

6-(4'-trifluoromethyl-6-methoxybiphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl esterMetformin

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 26, 2009

First Posted

March 30, 2009

Study Start

April 1, 2009

Primary Completion

October 1, 2009

Study Completion

October 1, 2009

Last Updated

November 18, 2023

Record last verified: 2023-04

Locations